Drug Trial Radar · NCT07520045
Biomarkers in Diabetic Retinopathy Treated With Faricimab vs Biosimilar Ranibizumab
Last checked: Nov 20, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Mar 12, 2026
Primary completion
Jun 1, 2027
Study completion Jun 1, 2027
Sponsor
- Lead sponsor
- Osijek University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 9, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to see if treatment with faricimab or biosimilar ranibizumab leads to different early imaging changes in adults with diabetic retinopathy requiring anti-VEGF treatment and to identify OCT and OCTA biomarkers predictive of differential early treatment response between the two therapies. The main questions it aims to answer are: Which OCT and OCT angiography biomarkers predict early treatment response? How do imaging biomarkers change after three loading doses of treatment? Are imaging biomarkers associated with systemic laboratory parameters? Researchers will compare faricimab to biosimilar ranibizumab to see if there are differences in imaging biomarkers and early treatment response. Participants will: * be randomized in a 1:1 ratio using a computer-generated randomization sequence * undergo comprehensive ophthalmic examinations, including visual acuity and intraocular pressure measurement * undergo OCT and OCT angiography imaging at each visit * receive three intravitreal injections during the loading phase * attend follow-up visits from baseline to 4-5 weeks after the third injection * provide blood samples for systemic laboratory analysis
Conditions
- Diabetic Retinopathy (DR)
- Diabetic Macular Edema (DME)
Interventions
FaricimabDrug
Faricimab will be administered via intravitreal injection.
Biosimilar ranibizumabDrug
Biosimilar ranibizumab will be administered via intravitreal injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Comparison of OCT and OCTA biomarkers associated with early anatomical treatment response to faricimab and biosimilar ranibizumabTime frame: From enrollment to 4-5 weeks after the third intravitreal injection
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Hospital Osijek
Osijek, Croatia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.